Osivax Launches Phase 2b Study of OVX836 for Influenza A

Osivax has vaccinated the first participant in a randomized, double-blind, multicenter phase 2b clinical trial (NCT05569239) evaluating OVX836, a broad-spectrum influenza A vaccine candidate. The study will assess…